Evidence map›Paper›PMID 41419734›Full record

ArticleNature communications2025

Recombination junctions from antibody isotype switching classify immune and DNA repair dysfunction.

Clara Vázquez García, Benedikt Obermayer, Baerbel Keller, Mikhail Lebedin, Christoph Ratswohl, Hassan Abolhassani, Antonia Busse, Michela Di Virgilio, Stephan Mathas, Dorothee Speiser and 4 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Clara Vázquez García *Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.ORCID http://orcid.org/0000-0003-4583-7616
Benedikt Obermayer *Core Unit Bioinformatics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0002-9116-630X
Baerbel KellerDepartment of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Mikhail LebedinMax Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.ORCID http://orcid.org/0000-0002-3877-7195
Christoph RatswohlMax Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.ORCID http://orcid.org/0000-0001-5413-0730
Hassan AbolhassaniDivision of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-4838-0407
Antonia BusseMax Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Michela Di VirgilioMax Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.ORCID http://orcid.org/0000-0001-5189-0793
Stephan MathasMax Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Dorothee SpeiserCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Dieter BeuleCore Unit Bioinformatics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
Qiang Pan-HammarströmDivision of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0003-1990-8804
Klaus WarnatzDepartment of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0002-1172-865X
Kathrin de la RosaMax Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany. Kathrin.delaRosa@helmholtz-hzi.de.ORCID http://orcid.org/0000-0003-4809-3157

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) 394523286EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 948464
6 · The paper itself

Abstract

Personalized assessment of immunocompetence and DNA double-strand break (DSB) repair requires methods that are sensitive to genetic and molecular complexity beyond the well-known monogenic disorders. Inspired by decades of research using B cells to study DNA repair processes, here we present SWIBRID (SWItch junction Breakpoint Repertoire IDentification), a tool to systematically profile genomic junctions generated in vivo during antibody class switch recombination (CSR) in B cells. As CSR junctions reflect immune diversity and DNA repair proficiency, SWIBRID detects phenotypic manifestations of deficiencies via a highly scalable, blood-based PCR followed by long-read sequencing and bioinformatic analysis. We show that specific DNA repair defects, including cancer-associated mutations, exhibit distinct CSR junction patterns. Notably, SWIBRID distinguishes different types of DSB repair knockouts and identifies the respective genetic defect in cell lines. In 68 patients, we detect immunodeficiencies and DNA repair defects with high accuracy (area under the curve 0.99 and 0.84, respectively), and identify previously uncharacterized patient groups as well as patient-specific CSR junction signatures. With SWIBRID, we seek to advance the identification of pathogenic defects, support early diagnosis, and address molecular heterogeneity that drives variable clinical outcomes.

Indexed as

DNA RepairImmunoglobulin Class SwitchingImmunoglobulin IsotypesImmunologic Deficiency SyndromesAnimalsB-LymphocytesDNA Breaks, Double-StrandedHumansMutationRecombination, GeneticImmunoglobulin Isotypes

Identifiers

PMID41419734
PMCPMC12722312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.